Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

788 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A, Vidal L, Shaw H, de Bono J. Reid A, et al. Among authors: shaw h. Eur J Cancer. 2007 Feb;43(3):481-9. doi: 10.1016/j.ejca.2006.11.007. Epub 2007 Jan 8. Eur J Cancer. 2007. PMID: 17208435 Review.
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. de Bono JS, et al. Among authors: shaw h. Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376. Clin Cancer Res. 2008. PMID: 18927309 Clinical Trial.
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS. Reid AH, et al. Among authors: shaw hm. Clin Cancer Res. 2009 Aug 1;15(15):4978-85. doi: 10.1158/1078-0432.CCR-09-0306. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638462 Free article. Clinical Trial.
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I. Ranson M, et al. Among authors: shaw h. Cancer Chemother Pharmacol. 2010 May;66(1):53-8. doi: 10.1007/s00280-009-1133-3. Epub 2009 Dec 3. Cancer Chemother Pharmacol. 2010. PMID: 19956953 Clinical Trial.
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. Molife LR, et al. Among authors: shaw hm. Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628389 Free PMC article. Clinical Trial.
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Yap TA, et al. Among authors: shaw h. J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679611 Clinical Trial.
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. Yap TA, et al. Among authors: shaw h. Br J Cancer. 2012 Apr 10;106(8):1379-85. doi: 10.1038/bjc.2012.99. Br J Cancer. 2012. PMID: 22491421 Free PMC article. Clinical Trial.
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, Szabo M, Upadhyay S, Califano R, Chan S, Lee L, Ali CW, Nicolson M, Bates AT, Button M, Chaudhuri A, Mulvenna P, Shaw HM, Danson SJ. Khan F, et al. Among authors: shaw hm. Eur J Cancer. 2014 Jul;50(10):1717-1721. doi: 10.1016/j.ejca.2014.03.001. Epub 2014 Apr 10. Eur J Cancer. 2014. PMID: 24726055
788 results